ALBANY, New York, October 29, 2012 /PRNewswire/ --
According to the latest market report published by Transparency Market Research (http://www.transparencymarketresearch.com) "Preimplantation Genetic Diagnosis (PGD) Market - Global Industry Analysis, Market Size, Market Share & Forecast 2012 - 2018," the global pre-implantation genetic diagnosis market was estimated to be worth USD 31.9 million in 2011 and is expected to reach USD 47.4 million in 2018, growing at a CAGR of 6.2% from 2013 to 2018. North America dominates the global demand for PGD, and is expected to account for over 30% of the global market followed by Europe at 28% in 2018.
Browse the full report at http://www.transparencymarketresearch.com/preimplantation-genetic-diagnosis-market.html
Some of the major drivers of the global PGD market are increase in the scope of direct to consumer genetic testing methods, increase in the number of cases of genetic diseases, the rising rate of infertility and the efficiency of PGD in assisting successful fetal implantation. PGD is adjunct to in vitro fertilization (IVF) and is employed for detection of any genetic abnormality in the embryo before it is implanted through IVF.
The major types of PGD testing are for determination of chromosomal abnormalities, detection of aneuploidy, HLA typing, gender selection and others. The major market for PGD exists in developed countries. However, emerging markets in the developing nations of Asia and rest of the world will grow with the advent of genetic diagnosis technology and awareness about prevention of genetic dis
|SOURCE Transparency Market Research|
Copyright©2012 PR Newswire.
All rights reserved